Drug Profile

Recombinant human thyroid stimulating hormone - Suzhou Zelgen Biopharmaceuticals

Alternative Names: rhTSH - Suzhou Zelgen Biopharmaceuticals

Latest Information Update: 14 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Suzhou Zelgen Biopharmaceuticals
Class Antineoplastics; Pituitary gonadotropins; Recombinant proteins
Mechanism of Action Thyrotropin replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preregistration Thyroid cancer

Most Recent Events

03 Jun 2024 Preregistration for Thyroid cancer (Diagnosis) in China (IM)
03 Jun 2024 Suzhou Zelgen Pharmaceuticals submits BLA to NMPA for Thyroid cancer (Diagnosis)
03 Jun 2024 Efficacy and adverse events data from a phase III trial in Thyroid cancer (Diagnosis) released by Suzhou Zelgen Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com